CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes.
CNS & Neurological Disorders - Drug Targetspublishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies.
As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
193rd of 261 in Neurosciences
166th of 261 in Pharmacology & Pharmacy
"This journal is the definitive source for the most meaningful and critical information available on CNS drug targets and progress both in industrial and academic based neurodegeneration research."
Rudolf E. Tanzi
Harvard Medical School, USA
Bentham Science is a science, technology, and medical (STM) publisher, providing academic researchers and industrial professionals with the latest information in diverse fields of science and technology. Our peer-reviewed scholarly journals and books have an ever-increasing readership of millions of researchers worldwide.
Bentham Science currently publishes more than 100 journals in both electronic and printed formats. Our journals cover various disciplines in pharmaceutical research and development, medical subspecialties, engineering, technology, and social sciences. The journals are indexed in recognized indexing agencies, such as Journal Citation Reports/Science Edition, MEDLINE/Index Medicus, PubMed, Scopus, Chemical Abstracts, EMBASE. ... Read More
